(NASDAQ: FLGC) Flora Growth's forecast annual revenue growth rate of N/A is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 2.53%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.31%.
Flora Growth's revenue in 2023 is N/A.On average, 2 Wall Street analysts forecast FLGC's revenue for 2023 to be $5,598,370,650, with the lowest FLGC revenue forecast at $5,393,316,300, and the highest FLGC revenue forecast at $5,803,425,000.
In 2024, FLGC is forecast to generate $6,964,110,000 in revenue, with the lowest revenue forecast at $6,964,110,000 and the highest revenue forecast at $6,964,110,000.